Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment

BACKGROUND: Recombinant human growth hormone (rhGH) is approved in Europe as a treatment for short children born small for gestational age (SGA) since 2003. However, no study evaluated the prevalence of SGA children with short stature who qualify for rhGH in Europe so far. This study aimed to invest...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ital J Pediatr
Egile Nagusiak: Tamaro, Gianluca, Pizzul, Mariagrazia, Gaeta, Giuliana, Servello, Raffaella, Trevisan, Marina, Böhm, Patricia, Materassi, Paola Manera Ada, Macaluso, Anna, Valentini, Denis, Pellegrin, Maria Chiara, Barbi, Egidio, Tornese, Gianluca
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://ncbi.nlm.nih.gov/pubmed/33794966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-021-01026-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak